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Increasing entomologic and epidemiologic evidence suggests that spotted fever group rickettsiae (SFGR) other than Rickettsia
rickettsii are responsible for spotted fever rickettsioses in the United States. A retrospective seroepidemiologic study was con-
ducted on stored acute- and convalescent-phase sera that had been submitted for Rocky Mountain spotted fever testing to the
North Carolina State Laboratory of Public Health. We evaluated the serologic reactivity of the paired sera to R. rickettsii, Rickett-
sia parkeri, and Rickettsia amblyommii antigens. Of the 106 eligible pairs tested, 21 patients seroconverted to one or more anti-
gens. Cross-reactivity to multiple antigens was observed in 10 patients, and seroconversions to single antigens occurred in 11
patients, including 1 against R. rickettsii, 4 against R. parkeri, and 6 against R. amblyommii. Cross-absorption of cross-reactive
sera and/or Western blots identified two presumptive cases of infection with R. parkeri, two presumptive cases of infection with
R. rickettsii, and one presumptive case of infection with R. amblyommii. These findings suggest that species of SFGR other than
R. rickettsii are associated with illness among North Carolina residents and that serologic testing using R. rickettsii antigen may
miss cases of spotted fever rickettsioses caused by other species of SFGR.
Rocky Mountain spotted fever (RMSF), caused by the bacte-rium Rickettsia rickettsii, is the most commonly reported fatal
tick-borne disease in the United States. The incidence of spotted
fever rickettsioses in the United States (including RMSF) has been
rising rapidly in recent years, from 2.5 cases per million in 2001 to
9.5 cases per million in 2011 (1). Mounting evidence suggests that
infections with other species of spotted fever group rickettsiae
(SFGR) may be at least partly responsible for the apparent increase
in cases, which may reflect an increase in reporting or incidence or
both. Seroepidemiologic surveys of adults and children in the
United States show that seroprevalence to SFGR is between 6%
and 12% (2, 3). Because subclinical infection or mild infections
with R. rickettsii are considered to be rare or even nonexistent and
there is cross-reactivity among SFGR in serologic tests, exposure
to other species of SFGR could account for this relatively high
seroprevalence (4). For many years, Rickettsia parkeri was consid-
ered to be a nonpathogenic SFGR, until it was isolated from a
patient in Virginia in 2002 (5). R. parkeri is now recognized as a
human pathogen, causing an illness characterized by formation of
an eschar at the site of inoculation and generally milder symptoms
than classic RMSF (6, 7). In California, Rickettsia 364D has been
implicated in causing an eschar-associated illness decades after it
was first identified in Dermacentor occidentalis ticks (8). Recent
studies have suggested that Rickettsia amblyommii, which is pres-
ent in a large percentage of Lone Star ticks (Amblyomma america-
num), may cause a mild rickettsiosis in humans (9–15). In this
study, we evaluated the reactivity of paired sera from North Car-
olina patients who had been tested for RMSF to a panel of SFGR,
including R. rickettsii, R. amblyommii, and R. parkeri.
MATERIALS AND METHODS
Selection of case patients. Case patients were identified from a database
of patients who were tested for RMSF at the North Carolina State Labo-
ratory of Public Health (NCSLPH) between 2008 and 2010. Samples were
submitted from across the entire state, with the majority from patients in
the Piedmont region (central North Carolina). Eligibility criteria included
having paired sera available (from the acute and convalescent phases) and
at least one sample with a titer of 1:64 against R. rickettsii in the original
test. Sera from patients tested for SFGR that do not demonstrate reactivity
are not routinely retained for long-term storage at the NCSLPH and were
therefore unavailable for testing. Patients were excluded from the study if
there was only a single serum specimen available, if there were not suffi-
cient sera remaining for additional testing, or if the sera could not be
located.
Antigens. Indirect immunofluorescence assay (IFA) testing com-
pleted at the North Carolina State Laboratory of Public Health (NCSLPH)
utilized rickettsiae grown in chicken egg yolk (R. rickettsii Sheila Smith) or
Vero cells (R. parkeri Portsmouth and R. amblyommii Darkwater) pro-
vided by William Nicholson, Rickettsial Zoonoses Branch, CDC (16).
Antigen preparations of infected Vero cells (R. parkeri and R. amblyom-
mii) or cell-free bacteria in egg yolk suspension (R. rickettsii) were spotted
onto the wells of glass templated slides using capillary tubes. Antigen spots
were allowed to air dry and then fixed in acetone for 10 to 15 min at room
temperature. Slides were then stored in sealed boxes at 70°C until they
were ready to be used. IFA testing conducted at the Tennessee Vector-
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Borne Disease Laboratory (TNVBDL) utilized slides prespotted with rick-
ettsiae grown in Vero cells (R. rickettsii Sheila Smith, R. parkeri Ports-
mouth, and R. amblyommii WB-82-like North Texas) and corresponding
Renografin-purified rickettsial lysates for cross-absorption and Western
blotting, prepared by Nicole Mendell, Department of Pathology, Univer-
sity of Texas Medical Branch at Galveston (17). Rickettsiae were cultivated
in confluent Vero cells and monitored until the cells were determined to
be approximately 70 to 80% infected. The infected monolayer was
scraped, harvested, washed with 0.1 M phosphate-buffered saline (PBS)
by centrifugation at 500  g for 5 min, and resuspended in PBS with 1%
bovine calf serum (BCS). The cell suspension was pipetted onto poly-L-
lysine-coated 12-well Teflon masked IFA slides at 10 l per well, allowed
to dry, and fixed for 10 min with acetone. The rickettsial antigen lysate was
generated by scraping heavily infected (80 to 100%) Vero cell monolayers
and centrifugation at 17,000  g for 15 min to pellet the infected Vero
cells. The infected Vero cells were resuspended in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS), 2 mM
L-glutamine, and 2 mM sucrose and lysed by sonication on ice for four
15-s pulses at 60% amplitude to release the rickettsiae. Host cell debris was
removed by centrifugation at 1,000  g for 5 min. The supernatant was
passed through a 0.22-m-pore syringe-driven filter, and cell-free rick-
ettsiae were pelleted 17,000  g for 15 min and resuspended in PBS with
0.05% sodium azide. Rickettsiae were sonicated on ice for eight 15-s
pulses at 60% amplitude to lyse the bacteria.
IFA. Assays were conducted using previously published methods for
rickettsial diagnosis using the IFA (18). Briefly, frozen slides were placed
at room temperature and allowed to warm while serial dilutions were
prepared. The primary dilution of 1:64 was prepared in 3% egg yolk for
the R. rickettsii antigen and 1% bovine serum albumin (BSA) in phos-
phate-buffered saline (PBS) for R. parkeri and R. amblyommii. The re-
maining serial 2-fold dilutions were made in PBS with 1% BSA for all
antigens. Sera were diluted to a final dilution of 1:2,048, except for posi-
tive-control sera, which were diluted to 1:16,384. Positive-control sera
from a patient with a known titer against R. rickettsii antigen were in-
cluded in each run (including dilutions from 1:64 to 1:16,384). Negative
controls, including PBS only, PBS with BSA, and a negative-control serum
that is nonreactive to R. rickettsii (primary dilution only) were also in-
cluded in each run. Dilutions were applied to the slides and incubated in a
humidity chamber at 37°C for 30 min. Slides were rinsed in PBS, washed
in PBS for 10 min, and then washed in distilled water for 10 min and air
dried. Fluorescein isothiocyanate (FITC)-labeled goat anti-human IgG
conjugate (Scimedx, Danville, NJ) with Eriochrome black counterstain
was applied to each well, and the wells were incubated in a humid
chamber at 37°C for 30 min. Slides were washed as described above,
and once dried, a drop of buffered glycerol was added to each well and
overlaid with a coverslip. Slides were stored in the dark until they were
read (within 24 h).
Reading of slides and interpretation of results. Paired sera were al-
ways tested and read together by the same technician. Slides were read on
a UV epifluorescence microscope, and wells were initially examined at low
power (100) and then high power (400). After the negative-control
wells were read, the positive-control and test samples were read from the
highest dilution to the lowest dilution. Staining for negative controls was
confirmed by the absence of specific fluorescence. Runs for which the
positive control was within one dilution of the known titer were consid-
ered acceptable. Fluorescence was scored according to brightness and
consistency of staining throughout the well on a scale of 4, 3, 2,
1, /, and , with 4 being the most intense fluorescence. Endpoint
titers were recorded as the reciprocal of the dilution with 1 fluorescence,
unless the fluorescence at the 1:2,048 dilution was 1 or greater, in which
case the endpoint titer was recorded as 1:2,048. If staining intensity did
not increase as expected from higher dilutions to lower dilutions or if
nonspecific staining patterns were observed, then this was noted, and
no endpoint titer could be determined. If a sample had a questionable
result or if problems with the staining were noted, the senior techni-
cian reevaluated the slide and either made the final call on the endpoint
titer or suggested that the test be repeated. If a test needed to be re-
peated, both samples (acute and convalescent phases) were repeated
together. For samples that did not yield a titer against R. rickettsii that
was within one dilution of the original titer, the assay was repeated, and
the titer that was found in the majority of the assays was accepted as the
correct titer.
A seroconversion was defined as a 4-fold or greater change in IgG
titer against an antigen between acute- and convalescent-phase sam-
ples. For each antigen, the patient was classified as either a serocon-
version, stationary titer (lack of 4-fold or greater change in titer), or
unknown (if one or more of the samples had nonspecific fluorescence
or were unreadable).
Cross-absorption and IFA. A subset of samples for which patient
clinical data and sufficient sera were available were selected for additional
analyses at the TNVBDL, in an attempt to identify the presumptive caus-
ative agent. Additional testing included Western blots and cross-absorp-
tion followed by IFA. To cross-absorb sera, equal volumes of diluted sera
(1:32) and antigen lysate (2 mg/ml) were incubated for 20 h at room
temperature on a rotator. Sera were then centrifuged at 10,000  g for 11
min, and the supernatant was collected for use in IFAs (19). IFAs were
completed as described above with the following modifications (accord-
ing to the protocol used at the TNVBDL): serum dilutions were prepared
in PBS with 1% BSA, 0.01% sodium azide, and 0.1% Tween 20, the wash
buffer was PBS with 0.1% Tween 20, FITC-labeled goat anti-human IgG
conjugate was purchased from KPL, and slides were counterstained with
1% Evans blue. A presumptive agent was identified when cross-absorp-
tion resulted in the removal (or at least 4-fold decrease) of both homolo-
gous and heterologous antibodies, while cross-absorption with the cross-
reactive species removed homologous antibodies only.
Western blotting. Purified antigen (30 g) was denatured with Run-
Blue dithiothreitol (DTT) reducer (Expedeon, San, Diego, CA) at 70°C for
10 min and separated by SDS-PAGE with a 4-to-12% gradient gel (Expe-
deon) using a Dual Cool electrophoresis system (CBS Scientific, San Di-
ego, CA) at 180 V for 1 h. Resolved antigens were transferred to nitrocel-
lulose membranes (Expedeon) using a semidry blotter (Amersham
Biosciences) at 22 V for 1 h. Membranes were blocked in Tris-buffered
saline (TBS; 10 mM Tris-HCl [pH 7.5], 150 mM NaCl) with 5% nonfat
dry milk for 1 h at room temperature. Sera, diluted 1:125 in blocking
buffer, were incubated with membranes overnight at room temperature.
Membranes were washed once in TBS with 0.05% Tween 20 for 10 min
and once in TBS for 10 min, followed by incubation with phosphatase-
labeled goat anti-human IgG purified antibody (KPL, Gaithersburg, MD)
diluted 1:20,000 in blocking buffer for 1 h at room temperature. Mem-
branes were washed twice in TBS for 10 min, and bands were visualized
using the BCIP/NBT (5-bromo-4-chloro-3-indolylphosphate–nitroblue
tetrazolium) phosphatase substrate (KPL) and washed in distilled water to
stop the reaction. Membranes were examined for the presence of the
typical rickettsial lipopolysaccharide (LPS) antigen washboard pattern at
20 to 60 kDa and specific protein antigens (SPAs) in the 110- to 140-kDa
region (20, 21).
Surveillance reports. Surveillance reports from the North Carolina
Division of Public Health (NCDPH) were requested for all patients in-
cluded in this study. Sample numbers from the NCSLPH were cross-
referenced with event numbers in the North Carolina Electronic Disease
Surveillance System (NCEDSS), and all available reports were provided in
paper format (deidentified) by the North Carolina Public Health Data
Group. A form was created in Qualtrics, and relevant fields were entered
into the form for each patient.
Data analysis. Standard descriptive statistics were calculated for de-
mographic and clinical variables. Positive percentage of agreement was
calculated for each antigen using seroconversion against R. rickettsii as the
referent comparison. All analyses were performed using SAS (version 9.2,
SAS Institute, Inc., Cary, NC).
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Human subjects. This research was approved by the Institutional Re-
view Board at the University of North Carolina at Chapel Hill. The use of
the data was approved by the North Carolina Division of Public Health
through a Data Use Agreement. Since all data were deidentified, informed
consent was not required as the risk to subjects was minimal.
RESULTS
Case patients. IFA test results from patients in the NCSLPH da-
tabase with paired sera that had been tested for RMSF between
2008 and 2010 were reviewed (n  311). Of these patients, 126
(40.5%) had at least one sample with a titer of 1:64 against R.
rickettsii. Results for testing against Rickettsia typhi were also re-
viewed for these patients, all of which were negative. Samples from
8 patients were no longer available. Twelve patients were excluded
from the analysis due to nonspecific fluorescence or an unreadable
result, and assays for 22 subjects were repeated for which endpoint
titers were all resolved. Endpoints were not reached for 11 sam-
ples, and these titers were recorded as 1:2,048. Of the 106 pa-
tients included in the study, surveillance reports were available for
53. The majority of these patients were white males, with a median
age of 50 (range, 1 to 80) (see Table S1 in the supplemental mate-
rial). The demographic profile was similar for patients who sero-
converted to at least one of the SFGR antigens and patients with
stationary titers.
Seroconversions. Of the 106 eligible pairs tested, 10 patients
seroconverted to R. rickettsii antigen in the original testing. In our
subsequent testing, only 8 of the 10 seroconverted to R. rickettsii
antigen. The two patients that seroconverted to R. rickettsii anti-
gen in the original testing but did not meet the criteria for sero-
conversion to R. rickettsii in subsequent testing both produced
titers that were within the one-dilution allowance for intra-assay
variability of the IFA. In our subsequent testing, one of these pa-
tients seroconverted to R. amblyommii antigen and the other did
not seroconvert to any of the SFGR antigens.
In this study, 21 patients seroconverted to one or more of the
SFGR antigens. The frequency of seroconversions to each antigen
and cross-reactivity between antigens is depicted in Fig. 1. Of the
eight patients that seroconverted to R. rickettsii, seven also sero-
converted to both R. parkeri and R. amblyommii. Eleven patients
had seroconversions against a single antigen: 1 against R. rickettsii,
4 against R. parkeri, and 6 against R. amblyommii. Three patients
had seroconversions against both R. parkeri and R. amblyommii
antigens.
The ability to detect seroconversions to R. parkeri and R. am-
blyommii using R. rickettsii antigen was poor, as measured by pos-
itive percentages of agreement of 50% (95% confidence interval
[CI], 24.0 to 76.0%) and 43.8% (95% CI, 20.8 to 69.4%), respec-
tively. The majority of positive agreement between seroconver-
sion classifications was due to broad cross-reactivity to all three
antigens.
Cross-absorption and Western blot assays. Convalescent-
phase sera from seven patients were cross-absorbed against all
three antigens followed by IFA. Patterns in IFA titers consistent
with R. parkeri infection were identified in patients 3 and 42, R.
rickettsii infection in patients 56 and 58, and R. amblyommii infec-
tion in patient 88 (Table 1). IFA patterns were indeterminate in
cross-absorbed sera from patients 68 and 70. Western blots of all
seven patient sera showed reactivity to LPS antigen from all three
species, but in many cases, specific protein antigens were not vis-
ible or were extremely faint (e.g., patients 68 and 88) (Fig. 2). In
contrast, the convalescent-phase serum from patient 42 was
clearly reactive with an 150-kDa protein of R. parkeri (Fig. 2),
supporting the results of the cross-absorption and IFA testing.
Clinical characteristics of seroconverters. Surveillance re-
ports were available for half of the patients (n  53). Of these, 12
reports were available from patients who seroconverted to at least
one of the SFGR antigens. Fever, thrombocytopenia, leukopenia,
elevated liver enzymes, and acute renal failure occurred more fre-
quently among seroconverters, while skin rash was more common
among patients who did not seroconvert (see Table S1 in the sup-
plemental material). None of the patients who seroconverted ex-
clusively to R. parkeri and/or R. amblyommii antigens reported a
rash, compared to three of five patients with seroconversions to
all three antigens. Hospitalization occurred in two serocon-
verters: in a patient who seroconverted to R. parkeri (patient 70)
and in another patient who seroconverted to R. amblyommii (pa-
tient 31, who also had a confirmed case of ehrlichiosis). Both Eh-
rlichia chaffeensis and R. amblyommii share a tick vector (A. ameri-
canum), thus this case was a potential coexposure.
DISCUSSION
The purpose of this study was to evaluate reactivity of paired sera
from suspected RMSF patients against R. rickettsii, R. parkeri, and
R. amblyommii antigens concurrently. These antigens are likely to
represent the species of SFGR that occur in tick vectors most fre-
FIG 1 Proportional Venn diagram showing seroconversions to R. rickettsii, R. parkeri, and R. amblyommii antigens and degree of cross-reactivity by indirect
immunofluorescent assay. The diagram was generated by a program available at http://www.cmbi.ru.nl/timhulse/venn/.
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quently in North Carolina, based on current knowledge. Although
the seroconversions observed cannot be used to infer etiology, the
greater number of unique seroconversions to R. parkeri and R.
amblyommii than to R. rickettsii indicates that species of SFGR
other than R. rickettsii may be causing infections among North
Carolina residents. This theory is supported by identification of R.
parkeri as the presumptive agent in two patients and R. amblyom-
mii in one patient using cross-absorption and Western blot assays.
The low positive percentage of agreement for R. parkeri and R.
amblyommii seroconversion classification also suggests that sero-
logic testing using R. rickettsii antigen may result in missed cases of
spotted fever rickettsioses caused by other species of SFGR. Thus,
even the current “gold standard” for serologic diagnosis of SFGR
has serious limitations.
The large relative frequency of seroconversions to R. amblyo-
mmii was not unexpected in the context of previous work by Ap-
person et al. (12). Active surveillance for tick-borne diseases in a
central North Carolina county resulted in the identification of
several patients with mild illness in which initial testing failed to
confirm RMSF. Upon further testing with both R. rickettsii and R.
amblyommii antigens, three patients seroconverted against R. am-
blyommii in that study. At this time, R. amblyommii has not been
recognized as a human pathogen, but the high infection preva-
lence in A. americanum, the most ubiquitous and aggressive hu-
man-biting tick in this region, creates ample opportunity for
potential infection of human and animal hosts (10, 13, 15). In
Oklahoma, canine infection with R. amblyommii was demon-
strated among dogs naturally exposed to ticks (22). In a longitu-
dinal study of outdoor workers in North Carolina, more than 90%
of ticks removed from subjects were A. americanum (23), while
less than 5% of ticks were D. variabilis and less than 1% of ticks
were Amblyomma maculatum (Charles Apperson, unpublished
data). The predominant rickettsial species found in ticks removed
from subjects in that study was R. amblyommii (51.6%), while R.
rickettsii was found in only one tick, an A. americanum nymph
(Apperson, unpublished).
We also anticipated that we would detect seroconversions to R.
parkeri, a known human pathogen that was found in 29% of gulf
coast ticks (Amblyomma maculatum) in a recent entomologic sur-
vey in North Carolina (24). A recent study identified R. parkeri in
Lone Star ticks from Tennessee and Georgia, suggesting that A.
americanum may serve as a vector for R. parkeri (25). Seroconver-
sions to R. parkeri and R. amblyommii among ill patients in this
study provide further evidence that infections caused by these
species of SFGR are likely to account for some of the increase in
spotted fever rickettsioses reported in this region.
It is well known that there is serologic cross-reactivity between
species of SFGR, and as a result, serologic tests cannot be used to
infer etiology (26). Serologic cross-reactivity between R. rickettsii
and R. parkeri antigens has been described previously. Raoult and
Paddock retested sera from 15 patients diagnosed with RMSF us-
ing class-specific IFA with R. rickettsii and R. parkeri antigens (27).
Equal titers were observed for six patients, while 4 patients had
higher titers to R. rickettsii and 5 patients had higher titers to R.
parkeri. Western blot analysis of 4 patients with higher titers
against R. parkeri provided additional evidence of infection with
R. parkeri. Paddock et al. conducted comparative class-specific
IFA with samples from 6 confirmed and 6 probable cases of R.
parkeri rickettsiosis using R. parkeri, R. rickettsii, R. amblyommii,
and Rickettsia akari antigens (28). IgG geometric mean titers were
FIG 2 Western blots of rickettsial antigens reacted with convalescent-phase patient sera (1:125 dilution). The bracket in the lower left indicates reactivity to
nonspecific LPS antigen, and the arrow indicates reactivity with a specific protein antigen.
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higher against R. rickettsii than for any other antigen. These stud-
ies illustrate that comparison of single titers is unreliable for dis-
tinguishing cases of RMSF and R. parkeri rickettsiosis. By evaluat-
ing reactivity of acute- and convalescent-phase paired sera, we
found that some patients showed rising or falling titers to multiple
rickettsiae, which is consistent with the cross-reactivity observed
in previous studies. It is also possible that patients could have been
coinfected with multiple species of rickettsiae or with species not
included in the testing for this study. Notably, we found that some
patients seroconverted to only a single antigen, indicating that
extensive cross-reactivity between SFGR antigens may not be
present in all cases.
Limitations of this study include the lack of clinical data for all
patients and the variability in the level of completeness of those for
which data are available. The small number of patients with sur-
veillance reports available prevents us from making conclusions
on the association between seroconversion to specific antigens
and clinical signs and symptoms. Due to the eligibility require-
ment of having paired sera, which represents a small minority of
patients, the patients in this study are likely to have suffered from
more severe illnesses, which led the medical provider to order
repeated testing for tick-borne pathogens. By limiting our study to
these patients, it is possible that we excluded many cases of mild
disease caused by SFGR. Curiously, there were some patients with
paired sera who had no reported signs or symptoms. In several
surveillance reports, it was noted that testing was done as a pre-
caution after multiple tick bites, although none of those patients
seroconverted in this study. The scarcity of appropriately timed
paired samples with accompanying clinical information further
compounds the diagnostic confusion for spotted fever rickettsio-
ses, indicating a need for acceptability criteria for serologic testing
of patient samples (29).
It is clear that while R. rickettsii is still circulating and causing
disease among people living in the southern and southeastern
United States, residents are also being infected with other SFGR
carried by ticks in these regions. Some of these SFGR, such as R.
parkeri, have been shown to cause human disease, while the patho-
genic potential of others, such as R. amblyommii, R. montanensis,
and R. rhipicephali, has yet to be determined. Until more specific
serologic diagnostic methods are developed that can distinguish
between species of SFGR or the use of molecular detection tech-
niques becomes routine, the relative contributions of different
species of SFGR to human morbidity will remain unclear. Active
surveillance for cases of suspected tick-borne illness, which in-
clude paired serology and molecular detection, are needed to de-
termine the etiologies of SFGR infections in this region. If current
serological methods continue to be the standard for diagnosis and
surveillance of spotted fever group rickettsioses, inclusion of an-
tigens for all species known to cause human disease in the relevant
geographic region should be considered to prevent missed cases.
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